Omnicell (NASDAQ:OMCL) Trading Up 4.7% – Should You Buy?

Shares of Omnicell, Inc. (NASDAQ:OMCL) shot up 4.7% on Monday . The stock traded as high as $34.88 and last traded at $34.62. 429,069 shares were traded during mid-day trading, a decline of 35% from the average session volume of 663,429 shares. The stock had previously closed at $33.08.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Down 1.8%

The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of 41.08, a PEG ratio of 0.88 and a beta of 0.97. The firm’s fifty day moving average is $39.66 and its 200-day moving average is $39.30. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, sell-side analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Institutional Trading of Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $313,044,000. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after acquiring an additional 137,834 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Omnicell by 4,074.3% during the 2nd quarter. California State Teachers Retirement System now owns 2,100,621 shares of the company’s stock valued at $87,218,000 after acquiring an additional 2,050,298 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after acquiring an additional 1,265,818 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after purchasing an additional 62,733 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.